5 Blue-Chip Dividend Stocks to Buy Before August Ends

Five dividend compounders announced near-term ex-dividend dates while pairing payouts with recent earnings beats or guidance raises: J&J declared a $1.34 quarterly dividend (ex-date Aug. 25, 2026) alongside raised full-year adjusted operational EPS guidance to $11.50–$11.65 and free cash flow approaching ~$21B; Coca-Cola raised full-year comparable EPS growth guidance to 9%–10% with ~$6.9B Q2 free cash flow; Exxon posted $23.6B operating cash flow and guided a free-cash-flow inflection after Guyana recovery, with a $1.03 quarterly dividend ex-date Aug. 17; Kimberly-Clark beat consensus in Q2 adjusted EPS ($2.12 vs $2.006) and maintained a 54-year dividend streak; PepsiCo lifted its dividend to $1.48 while H1 net revenue grew 7% and volume reaccelerated, though full-year EPS may land toward the low end. Overall tone is steady/defensive for income investors ahead of September payment cycles, with company-specific risks (biosimilar erosion at J&J, North America pacing at PepsiCo, APAC price/mix at KO, Middle East production exposure at Exxon, and China disinformation + Kenvue integration at KMB).

Analysis

This is less a “buy the dividend” setup than a quality-screen re-rating already in motion. The market is rewarding balance-sheet durability and cash conversion, but ex-dividend timing itself is mostly mechanical; the real edge comes from names where the payout is being funded by accelerating underlying cash flow rather than financial engineering.

Within the group, the strongest second-order setup is the one with the most operating leverage to a sustained commodity or volume tailwind: energy cash flow can reprice quickly, while staple cash flows tend to grind higher and then get partially absorbed by valuation. That makes the defensives heterogeneous — one can be a cash-flow accelerant, another a defensive compounder with valuation risk, and another a slow-burn execution story where headline yield masks incremental business risk.

The contrarian miss is that “Dividend King” status is not a catalyst by itself; it can trap capital into crowded low-volatility ownership just as multiples compress if rates back up or growth cools. The names with the best near-term asymmetry are those where guidance revisions can still surprise to the upside over the next 1-3 quarters, while the weakest are those facing discrete erosion or integration drag that can outpace the dividend yield over 6-18 months.

Key Decisions for Investors

• Overweight XOM versus the broader staples cohort for the next 1-3 months; the stock has the cleanest cash-flow convexity and the best ability to defend both buybacks and dividend growth. Falsify this with a sustained drop in crude or a sharp normalization of geopolitical risk.
• Pair trade: long PEP / short KMB on a 1-3 month horizon. PEP has improving volume inflection and a better path to multiple support; KMB’s execution and China-related noise make the yield look less secure on a relative basis. Cut the pair if KMB’s second-half headwind proves smaller than expected or PEP guidance reverts lower.
• Use JNJ as a core defensive hold only, not a tactical add, unless the market overreacts to biosimilar erosion. The name is quality, but the valuation already discounts a lot of durability; add only on a pullback or if forward EPS guidance is reaffirmed next quarter.
• Avoid initiating fresh longs in KO purely for the ex-dividend date; the stock’s defensiveness is well owned and the near-term catalyst is more about sentiment than earnings power. Better entry would be on a post-event pullback if emerging-market mix stabilizes.
• No trade on TGT from this tape; there is no company-specific catalyst here, so it belongs on the watch list only until there is evidence of margin or traffic improvement.